

TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS

Name of the Issue:

MedPlus Health Services Limited

1. Type of Issue (IPO/FPO)

IPO

2. Issue Size (Rs. Cr)

INR 1,398.295 Cr

3. Grade of issue along with name of the rating agency

Name

NA

Grade

NA

4. Subscription Level (Number of times)

The Offer was subscribed 52.8582 times (excluding the Anchor Investor Portion and after removing multiple and duplicate bids and technical rejection cases) *

*Source-Minutes of Basis of Allotment dated December 20, 2021

5. QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges

| Particulars | Percentage |
|---|-------------------|
| (i) allotment in the issue | 7.33%* |
| (ii) at the end of the 1st Quarter immediately after the listing of the issue ^{^^} | 31.14% |
| (iii) at the end of 1st FY (March 31, 2022)** | 32.21% |
| (iv) at the end of 2nd FY (March 31, 2023) [^] | NA |
| (v) at the end of 3rd FY (March 31, 2024) [^] | NA |

(*) As a % of total post issue paid up capital as per Prospectus dated December 16, 2021

([^]) QIB Holding not disclosed as reporting for relevant period / fiscal years has not been completed

^{^^} Shareholding Pattern filed with Stock Exchange for the quarter ended December 31, 2021

** Shareholding Pattern filed with Stock Exchange for the quarter ended March 31, 2022

6. Financials of the issuer (as per the annual financial results submitted to stock exchanges)

Consolidated

(Rs in Crores)

| Parameters | 1st FY (March 31, 2022)** | 2nd FY (March 31, 2023)* | 3rd FY (March 31, 2024)* |
|---|---------------------------|--------------------------|--------------------------|
| Income from operations | 3779.27 | N.A. | N.A. |
| Net Profit for the period | 94.71 | N.A. | N.A. |
| Paid-up equity share capital | 23.86 | N.A. | N.A. |
| Reserves excluding revaluation reserves | 1393.91 | N.A. | N.A. |

Standalone

(Rs in Crores)

| Parameters | 1st FY (March 31, 2022)** | 2nd FY (March 31, 2023)* | 3rd FY (March 31, 2024)* |
|---|---------------------------|--------------------------|--------------------------|
| Income from operations | 145.71 | N.A. | N.A. |
| Net Profit for the period | 5.57 | N.A. | N.A. |
| Paid-up equity share capital | 23.86 | N.A. | N.A. |
| Reserves excluding revaluation reserves | 1088.92 | N.A. | N.A. |

* Financials not disclosed as reporting for the relevant fiscal years has not been completed.

** Source: Audited Financial Statements as submitted to the Stock Exchange for the financial year ended March 31, 2022

7. Trading Status in the scrip of the issuer

Company's Equity Shares are listed on both the BSE Limited and the National Stock Exchange of India Limited.

| Particulars | Status |
|--|-------------------|
| (i) at the end of 1st FY (March 31, 2022) | Frequently Traded |
| (ii) at the end of 2nd FY (March 31, 2023)* | N.A. |
| (iii) at the end of 3rd FY (March 31, 2024)* | N.A. |

* Trading status not disclosed as reporting for the relevant fiscal years has not been completed

Source: BSE

8. Change in Directors of issuer from the disclosures in the offer document

| Particulars | Name of the Director | Appointed / Resigned |
|--|----------------------|----------------------|
| (i) at the end of 1st FY (March 31, 2022) | None | None |
| (ii) at the end of 2nd FY (March 31, 2023)*# | N.A. | N.A. |
| (iii) at the end of 3rd FY (March 31, 2024)* | N.A. | N.A. |

*Changes in directors not disclosed as reporting for relevant fiscal years has not been completed

However, until November 15, 2022 there has been no change on the Board

9. Status of implementation of project/ commencement of commercial production

- (i) As disclosed in the offer document: NA
- (ii) Actual implementation: NA
- (iii) Reasons for delay in implementation, if any: NA

10. Status of utilization of issue proceeds

- (i) As disclosed in the offer document:

(Rs. In Million)

| Particulars | Amount to be funded from the Net Proceeds | Estimated deployment | | |
|--|---|----------------------|-----------------|-----------------|
| | | Fiscal 2022 | Fiscal 2023 | Fiscal 2024 |
| Investment into our Material Subsidiary, Optival for funding working capital requirements of Optival | 4,671.70 | 1,239.19 | 1,586.87 | 1,845.64 |
| General corporate purposes | 1,055.71 | 500 | 555.71 | - |
| Total | 5,727.41 | 1,739.19 | 2,142.58 | 1,845.64 |

- (ii) Actual utilization:

(Rs. In Million)

| Item Head | Amount as proposed in Offer Document | Amount utilized | | | Total unutilized amount as on (September 30, 2022) |
|--|--------------------------------------|---|------------------------------------|--|--|
| | | As at the beginning of the quarter (July 1, 2022) | During the Quarter (Jul-Sep, 2022) | At the end of quarter (September 30, 2022) | |
| Investment into our Material Subsidiary, Optival for funding working capital requirements of Optival | 4,671.70 | 2,826.06 | - | 2,826.06 | 1,845.64 |
| General Corporate Purpose | 1,085.89 | 9.089 | 106.18 | 115.27 | 970.62 |

| | | | | | |
|-------|----------|----------|--------|----------|----------|
| Total | 5,757.59 | 2,835.15 | 106.18 | 2,941.33 | 2,816.26 |
|-------|----------|----------|--------|----------|----------|

Source: Monitoring Agency report dated, November 10, 2022 for the Quarter ended September 30, 2022.

General Corporate Purpose Amount has increase due to reduction in Offer expense.

* Rs 280,79,40,346 is deployed into Fixed Deposit and Rs. 83,20,031 is kept in Axis bank IPO Escrow Account.

(iii) Reasons for deviation, if any: None

Source: Monitoring Agency report dated, November 10, 2022 for the Quarter ended September 30, 2022.

11. Comments of monitoring agency, if applicable

| | |
|--|------|
| (a) Comments on use of funds | None |
| (b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document | |
| (c) Any other reservations expressed by the monitoring agency about the end use of funds | |

Source: Monitoring Agency report dated, November 10, 2022 for the Quarter ended September 30, 2022.

12. Pricing Data

| | |
|-----------------------------------|-------------------|
| Issue Price (Rs.): | 796/- |
| Designated Stock Exchange: | BSE |
| Listing Date: | December 23, 2021 |

| Price parameters | At close of listing day (i.e. December 23, 2021) | At close of 30th calendar day from listing day | At close of 90th calendar day from listing day | As at the end of 1st FY after the listing of the issue (March 31, 2022) | | |
|---|--|--|--|---|----------------------|---------------------|
| | | | | Closing price | High (during the FY) | Low (during the FY) |
| Market Price on Designated Stock Exchange (BSE) | 1,120.85 | 1219.65 | 979.55 | 1010.25 | 1343 | 921 |
| BSE SENSEX | 57,315.28 | 59037.18 | 57989.3 | 58568.51 | 62245.43 | 47204.5 |
| Sectoral Index | NA | NA | NA | NA | NA | NA |

| Price parameters | As at the end of 2nd FY after the listing of the issue (March 31, 2023)* | | | As at the end of 3rd FY after the listing of the issue (March 31, 2024)* | | |
|---|--|----------------------|---------------------|--|----------------------|---------------------|
| | Closing price | High (during the FY) | Low (during the FY) | Closing price | High (during the FY) | Low (during the FY) |
| Market Price on Designated Stock Exchange (BSE) | NA | NA | NA | NA | NA | NA |
| BSE SENSEX | NA | NA | NA | NA | NA | NA |
| Sectoral Index | NA | NA | NA | NA | NA | NA |

Source: BSE website

* Pricing Data not disclosed as reporting for the relevant fiscal years has not been completed

13. Basis for Issue Price (Source of accounting ratios of peer group and industry average may be indicated; Source of the accounting ratios may generally be the same, however in case of different sources, reasons for the same may be indicated)

| Accounting ratio | | As disclosed in the offer document ⁽¹⁾ | At the end of 1st FY (March 31, 2022) ⁽⁴⁾ | At the end of 2nd FY (March 31, 2023) ⁽²⁾ | At the end of 3rd FY (March 31, 2024) ⁽²⁾ |
|------------------|-----------------------------|---|--|--|--|
| EPS | Issuer: | -- | -- | -- | -- |
| | Consolidated (Basic) | 5.99 | 8.55 | N.A | N.A |
| | Consolidated (Diluted) | 5.75 | 8.52 | N.A | N.A |
| | Peer Group ⁽³⁾ : | NA | NA | NA | NA |
| | Industry Avg: | NA | N.A | N.A | N.A |
| P/E | Issuer: | -- | -- | -- | -- |
| | Consolidated (Basic) | 132.89 | 118.16 | N.A | N.A |
| | Consolidated (Diluted) | 138.43 | 118.57 | N.A | N.A |
| | Peer Group ⁽³⁾ : | NA | NA | NA | NA |
| | Industry Composite: | NA | N.A | N.A | N.A |
| RoNW (%) | Issuer: | -- | -- | -- | -- |
| | Consolidated | 8.74 | 0.50 | N.A | N.A |

| | | | | | |
|-----|-----------------------------|-------|-------|-----|-----|
| | Peer Group ⁽³⁾ : | NA | NA | NA | NA |
| | Industry Composite: | NA | N.A | N.A | N.A |
| NAV | Issuer: | -- | -- | -- | -- |
| | Consolidated | 65.37 | 93.28 | N.A | N.A |
| | Peer Group ⁽³⁾ : | NA | NA | NA | NA |
| | Industry Avg: | NA | N.A | N.A | N.A |

Notes:

- (1) Prospectus dated December 16, 2021
- (2) Not disclosed as the reporting for the relevant fiscal years has not been completed.
- (3) There are no listed companies in India that engage in a business similar to that of the Company. Accordingly, it is not possible to provide an industry comparison in relation to the Company
- (4) Source: Audited Financial Statements as submitted to the Stock Exchange for the financial year ended March 31, 2022

14. Any other material information

| Particulars | Date |
|--|-------------------|
| The Company has informed the Exchange that Mr. Parag Jain, Company Secretary and Compliance Officer has resigned w.e.f January 14, 2022. He has also ceased to be the Company Secretary of the Company's Subsidiary and Material Subsidiary. | January 13, 2022 |
| The Company has informed the Exchange that Ms. Shilpi Keswani is appointed as the Company Secretary and Compliance Officer w.e.f January 15, 2022 | January 13, 2022 |
| The Company has informed the Exchange that the new Registered Office of the Company is H. No: 11-6-56, Survey No: 257 & 258/1, Opp: IDPL Railway Siding Road, Moosapet, Kukatpally, Hyderabad - 500037, Telangana, India with effect from 2nd May, 2022 | May 3, 2022 |
| The Company has informed the Exchange that Mr. Hemanth Kundavaram has resigned from the post of Chief Financial Officer ('CFO') and Key Managerial Personnel of the MedPlus Health Services Limited ('Company'), Optival Health Solutions Private Limited and Wynclark Pharmaceuticals Private Limited, subsidiaries of the Company. Mr. Kundavaram will continue to act as the CFO of the Company until Sunday, 5th June, 2022. | June 4, 2022 |
| The Company has informed the Exchange that the Company has incorporated a wholly-owned subsidiary namely, 'MedPlus Insurance Brokers Private Limited'. As per the Certificate of Incorporation dated 14th July 2022 issued by the Registrar of Companies, Ministry of Corporate Affairs, the date of incorporation of wholly-owned subsidiary is 14th July, 2022. | July 15, 2022 |
| The Company has informed the Exchange that Mr. Sujit Kumar Mahato, as Chief Financial Officer of the Company with effect from 11th November, 2022 | November 11, 2022 |

Source- Stock Exchange Filings

All the above information has been updated till November 15, 2022 unless indicated otherwise